Wu Ian, Parikh Chirag R
Section of Nephrology, Yale University, New Haven, Connecticut, USA.
Clin J Am Soc Nephrol. 2008 Nov;3(6):1895-901. doi: 10.2215/CJN.02030408. Epub 2008 Oct 15.
Biomarkers have been used to screen for kidney disease since creatinine was recognized to be correlated with renal function. The measurement of serum creatinine as a screening test for kidney disease falls short, however, because serum creatinine is not particularly sensitive for the diagnosis of kidney disease. Creatinine reflects renal filtering capacity, which has a lot of reserve and is therefore not sensitive to acute or chronic kidney injury unless the injury is substantial enough to compromise the filtering ability. The sensitivity of serum creatinine is further diminished in certain patient populations that are prone to kidney disease because of the physiology of creatinine. Therefore, researchers are seeking new biomarkers that can aid in the diagnosis of both acute and chronic kidney diseases. The limitations of creatinine in screening for kidney diseases in specific patient populations as well as new potential biomarkers that are actively being researched are discussed in this review.
自从肌酐被认为与肾功能相关以来,生物标志物就一直被用于肾脏疾病的筛查。然而,将血清肌酐作为肾脏疾病的筛查指标存在不足,因为血清肌酐对肾脏疾病的诊断并不特别敏感。肌酐反映肾脏的滤过能力,而这种能力有很大的储备,因此除非损伤足够严重以至于损害滤过能力,否则对急性或慢性肾损伤并不敏感。由于肌酐的生理特性,在某些易患肾脏疾病的患者群体中,血清肌酐的敏感性会进一步降低。因此,研究人员正在寻找能够辅助诊断急性和慢性肾脏疾病的新型生物标志物。本综述讨论了肌酐在特定患者群体中筛查肾脏疾病时的局限性以及正在积极研究的新的潜在生物标志物。